stoxline Quote Chart Rank Option Currency Glossary
BioLineRx Ltd. (BLRX)
0.6309  -0.004 (-0.65%)    06-18 12:02
Open: 0.65
High: 0.6599
Volume: 92,469
Pre. Close: 0.635
Low: 0.626
Market Cap: 55(M)
Technical analysis
2024-06-18 11:49:02 AM
Short term     
Mid term     
Targets 6-month :  0.88 1-year :  0.99
Resists First :  0.75 Second :  0.85
Pivot price 0.69
Supports First :  0.6 Second :  0.49
MAs MA(5) :  0.65 MA(20) :  0.68
MA(100) :  0.9 MA(250) :  1.31
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  8.1 D(3) :  16.5
RSI RSI(14): 43.1
52-week High :  2.52 Low :  0.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BLRX ] has closed above bottom band by 17.5%. Bollinger Bands are 39.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.66 - 0.66 0.66 - 0.67
Low: 0.62 - 0.63 0.63 - 0.63
Close: 0.63 - 0.64 0.64 - 0.65
Company Description

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Headline News

Sun, 16 Jun 2024
Short Interest in BioLineRx Ltd. (NASDAQ:BLRX) Grows By 62.6% - Defense World

Sat, 15 Jun 2024
Reviewing BioLineRx (NASDAQ:BLRX) & Entrada Therapeutics (NASDAQ:TRDA) - Defense World

Fri, 14 Jun 2024
BioLineRx Ltd. (NASDAQ:BLRX) Sees Large Increase in Short Interest - MarketBeat

Fri, 14 Jun 2024
BLRX - BioLineRx Reports Second Quarter 2011 Financial Results -

Thu, 13 Jun 2024
Equities Analysts Set Expectations for BioLineRx Ltd.'s Q2 2024 Earnings (NASDAQ:BLRX) - MarketBeat

Tue, 11 Jun 2024
BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session - Yahoo Movies UK

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 80 (M)
Shares Float 990 (M)
Held by Insiders 8.5 (%)
Held by Institutions 1.7 (%)
Shares Short 219 (K)
Shares Short P.Month 784 (K)
Stock Financials
EPS -0.76
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -247.2 %
Return on Assets (ttm) -38.3 %
Return on Equity (ttm) -189.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.06
EBITDA (p.s.) -0.53
Qtrly Earnings Growth 0 %
Operating Cash Flow -23 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -0.84
PEG Ratio 0
Price to Book value 63.18
Price to Sales 10.52
Price to Cash Flow -2.24
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android